Resources

Novel Coronavirus (COVID-19) Vaccine Development – Wave 2

Given the recent uptick in COVID-19 cases in the US, many InCrowd panelists have been reporting that they do not expect things to return to normal until a vaccine is developed and disseminated. In order to deepen our understanding of the COVID-19 vaccine landscape, we surveyed infectious disease specialists across the country to get their perception and predictions on the efficacy, impact, and competitive landscape of COVID-19 vaccines.*

* Please note, views in this survey reflect opinions only as reported by responding physicians.

Methodology:

  • Method:
    • 12-Minute MicroSurvey via InCrowd
  • Crowds:
    • Infectious disease doctors
  • Sample Size:
    • n = 100
      • Community Hospital, Academic Hospital, Office-based
  • Fielding Period:
    • October 22nd – 26th

InCrowd’s other COVID-19 Tracking Reports:

Please fill out the form below to access this content

Name(Required)
Consent
This field is for validation purposes and should be left unchanged.

Related Resources

The Impact of Technology on Mental Healthcare

The Impact of Technology on Mental Healthcare

Exploring Psychiatrist Opinions and Expectations Around the Rise in Digital Therapeutics to Treat Mental Health The National Institutes of Health (NIH) believe “technology has opened a new frontier in mental health support,” but questions remain around how...

read more
ESMO 2022 Real-Time Roundup

ESMO 2022 Real-Time Roundup

The 2022 Annual Meeting of the European Society for Medical Oncology (ESMO) took place in person from September 9th to the 13th. InCrowd wanted to learn from those Medical Oncologists and Hematology-Oncologists who attended the following two objectives: Explore which...

read more
ASCO 2022 Real-Time Roundup

ASCO 2022 Real-Time Roundup

The 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) took place in person from June 3rd to the 7th. InCrowd wanted to learn from those oncologists who attended the following two objectives: Explore which tumor type/track had the most exciting...

read more